Metabolic syndrome as an indicator of high cardiovascular risk in patients with diabetes: Analyses based on Korea National Health and Nutrition Examination Survey (KNHANES) 2008

Diabetology & Metabolic Syndrome

Jeong-taek Woo¹  Young Seol Kim¹  Sang Ouk Chin¹  Jung Il Son¹  Jin Kyung Hwang¹  So Young Park¹  Sang Youl Rhee¹ 

[1] Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, 1 Hoegi-dong, Dongdaemoon-gu, Seoul 130-702, South Korea

关键词: Korea;    KNHANES;    Cholesterol;    Dyslipidemia;    DM;    Diabetes mellitus;    Framingham risk score;    Cardiovascular disease;    Syndrome X;    Metabolic syndrome;   

Others  :  1115003
DOI  :  10.1186/1758-5996-6-98

 received in 2014-05-20, accepted in 2014-09-03,  发布年份 2014

【 摘 要 】

Background

Patients with either diabetes mellitus (DM) or metabolic syndrome (MS) are recognized as a high risk group for cardiovascular disease (CVD). Several studies have demonstrated the clinical value of MS for predicting additional CVD risk in the DM population, although the clinical significance remains debatable.

Methods

We used the Korea National Health and Nutrition Examination Survey (KNHANES) 2008, which is the national representative database. We classified the KNHANES subjects based on MS and glucose tolerance status, and compared clinical characteristics and future CVD risk among the subgroups.

Results

A total of 796 of the 4314 subjects were diagnosed with MS. Their clinical characteristics were significantly different from patients without MS. Prevalence of DM was 9.5% in subjects with MS, but only 1.1% in subjects without MS. In addition, there was no MS in 30.9% of total DM patients who were enrolled in this study. For the normal and impaired fasting glucose subgroups, the prevalence of moderate (5–10%) and high (>10%) CVD risk was significantly higher in patients with MS than in patients without MS (p < 0.001). However, in the DM subgroup, even after multiple adjustments, there were no differences in clinical characteristics or in the prevalence of moderate to high CVD risk according to MS status. That said, LDL cholesterol in the DM group without MS was significantly higher than in the DM group with MS (p = 0.010).

Conclusions

The efficacy of MS as a screening tool for high CVD risk may be limited in DM patients, and conventional risk factors such as LDL may be more important.

【 授权许可】

   
2014 Rhee et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
• [2]Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
• [3]Alberti KG, Zimmet P, Shaw J: The metabolic syndrome–a new worldwide definition. Lancet 2005, 366:1059-1062.
• [4]Grundy SM: Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008, 28:629-636.
• [5]Expert Panel on Detection E: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA: J Am Med Assoc 2001, 285:2486-2497.
• [6]Grundy SM: Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007, 92:399-404.
• [7]Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM: Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007, 49:403-414.
• [8]Zhang ML, Hou XH, Zhu YX, Lu JX, Peng LP, Gu HL, Jia WP: Metabolic disorders increase the risk to incident cardiovascular disease in middle-aged and elderly Chinese. Biomed Environ Sci 2012, 25:38-45.
• [9]Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
• [10]Park HS, Park CY, Oh SW, Yoo HJ: Prevalence of obesity and metabolic syndrome in Korean adults. Obes Rev 2008, 9:104-107.
• [11]D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB: General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008, 117:743-753.
• [12]Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
• [13]American DA: Diagnosis and classification of diabetes mellitus. Diabetes Care 2012, 35(Suppl 1):S64-S71.
• [14]Koh DH, Kim HR, Han SS: The relationship between chronic rhinosinusitis and occupation: the 1998, 2001, and 2005 Korea National health and nutrition examination survey (KNHANES). Am J Ind Med 2009, 52:179-184.
• [15]Romain S, Dussert C, Martin PM: Determination of oestrogen receptors: application of the Passing-Bablock linear regression technique for comparison of enzyme immunoassay and radioligand binding assay in 1841 breast cancer tumours. Eur J Cancer 1991, 27:715-720.
• [16]Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
• [17]Gonzalez-Granado LI: Reply: presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM 2009, 102:889.
• [18]Pawate S, Moses H, Sriram S: Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM 2009, 102:449-460.
• [19]Levy JC, Matthews DR, Hermans MP: Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998, 21:2191-2192.
• [20]Wallace TM, Levy JC, Matthews DR: Use and abuse of HOMA modeling. Diabetes Care 2004, 27:1487-1495.
• [21]Hanley AJ, Wagenknecht LE, D'Agostino RB Jr, Zinman B, Haffner SM: Identification of subjects with insulin resistance and beta-cell dysfunction using alternative definitions of the metabolic syndrome. Diabetes 2003, 52:2740-2747.
• [22]Ford ES: Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005, 28:1769-1778.
• [23]Osuji CU, Nzerem BA, Dioka CE, Onwubuya EI: Metabolic syndrome in newly diagnosed type 2 diabetes mellitus using NCEP-ATP III, the Nnewi experience. Niger J Clin Pract 2012, 15:475-480.
• [24]Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Runzo C, Prina Cerai S, Pagano G, Cavallo-Perin P: Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2004, 27:2689-2694.
• [25]Najarian RM, Sullivan LM, Kannel WB, Wilson PW, D'Agostino RB, Wolf PA: Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch Intern Med 2006, 166:106-111.
• [26]Kahn R, Buse J, Ferrannini E, Stern M, American Diabetes A: The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289-2304.
• [27]Harrison's principles of internal medicine 18th edition. 2011, 2985-2986. [Diabetes Mellitus, Volume 344]
• [28]Liao YF, Feng Y, Chen LL, Zeng TS, Yu F, Hu LJ: Coronary heart disease risk equivalence in diabetes and arterial diseases characterized by endothelial function and endothelial progenitor cell. J Diabetes Complications 2014, 28:214-218.
• [29]Liang KW, Lee WJ, Lee WL, Chen YT, Ting CT, Sheu WH: Diabetes exacerbates angiographic coronary lesion progression in subjects with metabolic syndrome independent of CRP levels. Clin Chim Acta; Int J Clin Chem 2008, 388:41-45.
• [30]Li M, Li Y, Liu J: Metabolic syndrome with hyperglycemia and the risk of ischemic stroke. Yonsei Med J 2013, 54:283-287.
• [31]Kim JY, Choi EY, Mun HS, Min PK, Yoon YW, Lee BK, Hong BK, Rim SJ, Kwon HM: Usefulness of metabolic syndrome score in the prediction of angiographic coronary artery disease severity according to the presence of diabetes mellitus: relation with inflammatory markers and adipokines. Cardiovasc Diabetol 2013, 12:140. BioMed Central Full Text
• [32]Rodondi N, Locatelli I, Aujesky D, Butler J, Vittinghoff E, Simonsick E, Satterfield S, Newman AB, Wilson PW, Pletcher MJ, Bauer DC: Framingham risk score and alternatives for prediction of coronary heart disease in older adults. PLoS One 2012, 7:e34287.
• [33]Zomer E, Liew D, Owen A, Magliano DJ, Ademi Z, Reid CM: Cardiovascular risk prediction in a population with the metabolic syndrome: Framingham vs. UKPDS algorithms. Eur J Prev Cardiol 2014, 21:384-90.
• [34]Kannel WB, McGee D, Gordon T: A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976, 38:46-51.